| Contact, Site Public |
NCT02616302 / 2014-004506-15: A Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children |
|
|
| Recruiting | 2 | 70 | Europe, Canada, US, RoW | Dexlansoprazole, Dexilant | Takeda | Gastroesophageal Reflux Disease (GERD) | 01/25 | 01/25 | | |
NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases |
|
|
| Recruiting | 2 | 44 | US | Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy | SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences | Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8 | 02/25 | 12/26 | | |
NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) |
|
|
| Recruiting | 2 | 40 | Europe, US, RoW | TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930 | Takeda, Takeda Development Center Americas, Inc. | Thrombotic Thrombocytopenic Purpura (TTP) | 03/25 | 03/25 | | |
| Active, not recruiting | 2 | 357 | Europe, Canada, US | TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar | Takeda | Celiac Disease | 05/25 | 05/25 | | |
NCT05673785: A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) |
|
|
| Recruiting | 2 | 52 | RoW | Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Prednisone | Takeda | Lymphoma | 07/25 | 12/27 | | |
| Recruiting | 2 | 138 | Europe, Japan, US | TAK-341, MEDI1341, Placebo | Takeda, AstraZeneca | Multiple System Atrophy | 08/25 | 08/25 | | |
NCT05890352: Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment |
|
|
| Recruiting | 2 | 227 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Tazemetostat, E7438, EPZ-6438, EPZ6438, Zanubrutinib, BGB-3111, Brukinsa, BTK-InhB | SWOG Cancer Research Network, National Cancer Institute (NCI), BeiGene, Ipsen, Incyte Corporation | Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma | 12/26 | 01/29 | | |
| Recruiting | 2 | 76 | Europe, Canada, US, RoW | Dexlansoprazole, Dexilant | Takeda | Erosive Esophagitis | 11/27 | 11/27 | | |
| Active, not recruiting | 2 | 27 | US | TAK-007, Chemotherapy Agents | Takeda | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | 10/25 | 06/30 | | |
NCT04776018: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Terminated | 1/2 | 27 | Canada, US | TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj | Takeda | Relapsed and/or Refractory Multiple Myeloma (RRMM) | 08/23 | 11/23 | | |
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors |
|
|
| Completed | 1/2 | 45 | US, RoW | Modakafusp Alfa, TAK-573, Pembrolizumab | Takeda | Neoplasms, Melanoma | 11/23 | 11/23 | | |
| Active, not recruiting | 1/2 | 336 | Europe, Canada, Japan, US, RoW | Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone | Takeda | Multiple Myeloma | 02/24 | 09/24 | | |
NCT04501614 / 2019-002549-39: A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
|
|
| Active, not recruiting | 1/2 | 68 | Europe, US, RoW | Ponatinib, Ponatinib AAF, Chemotherapy Agents | Takeda, Takeda Development Center Americas, Inc. | Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL) | 12/24 | 01/27 | | |
| Recruiting | 1/2 | 182 | Europe, Canada, US, RoW | TAK-280 | Takeda, Takeda Development Center Americas, Inc. | Unresectable Locally Advanced or Metastatic Cancer | 02/25 | 07/26 | | |
| Active, not recruiting | 1/2 | 58 | Europe, Canada, US, RoW | Modakafusp Alfa, TAK-573, Daratumumab | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 03/25 | 03/25 | | |
NCT05070247: A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 313 | US | TAK-500, Pembrolizumab | Takeda | Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous | 08/26 | 08/26 | | |
| Active, not recruiting | 1/2 | 334 | Europe, Japan, US, RoW | TAK-788, AP32788 | Takeda | Carcinoma, Non-Small-Cell Lung | 03/25 | 03/25 | | |
|
|
NCT04844073: A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer |
|
|
| Recruiting | 1/2 | 258 | US, RoW | TAK-186, MVC-101 | Takeda | Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer | 09/25 | 11/26 | | |
| Recruiting | 1/2 | 368 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
| Active, not recruiting | 1/2 | 49 | Europe, Japan, US, RoW | TAK-981, Pembrolizumab | Takeda, Takeda Development Center Americas, Inc. | Advanced or Metastatic Solid Tumors | 11/25 | 11/25 | | |
NCT05886491: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 53 | US | GDX012, Chemotherapy Agents | Takeda | Leukemia | 04/26 | 06/27 | | |
| Completed | 1 | 80 | US | TAK-105-a, TAK-105-a Placebo, TAK-105-b, TAK-105-b Placebo | Takeda | Healthy Volunteers | 06/23 | 06/23 | | |
| Completed | 1 | 24 | US | TAK-227 | Takeda | Healthy Volunteers | 06/23 | 06/23 | | |
NCT05602818: A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience |
|
|
| Completed | 1 | 67 | US | Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg, Alprazolam, Placebo | Takeda | Healthy Volunteers | 06/23 | 07/23 | | |
NCT05995249: A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults |
|
|
| Completed | 1 | 172 | US | TAK-279, Erythromycin, Phenytoin, Efavirenz | Takeda | Healthy Volunteers | 12/23 | 12/23 | | |
NCT06132867: A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults |
|
|
| Completed | 1 | 12 | US | Brigatinib, ALUNBRIG® | Takeda | Healthy Volunteers | 02/24 | 02/24 | | |
NCT04879849: A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers |
|
|
| Completed | 1 | 34 | US | Pembrolizumab, TAK-676, Image-guided radiation therapy | Takeda | Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck | 04/24 | 04/24 | | |
NCT06258265: A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements |
|
|
| Recruiting | 1 | 120 | US | TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo | Takeda | Healthy Volunteers | 06/24 | 07/24 | | |
NCT05976321: A Study of TAK-279 in Adults With or Without Liver Damage |
|
|
| Recruiting | 1 | 32 | US | TAK-279 | Takeda | Hepatic Impairment, Healthy Volunteers | 08/24 | 08/24 | | |
| Terminated | 1 | 14 | US | MT-0169 | Molecular Templates, Inc. | Relapsed and/or Refractory Multiple Myeloma | 12/23 | 12/23 | | |
NCT05976334: An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 10 | Europe | [14C] Subasumstat, TAK-981, Subasumstat | Takeda | Solid Tumors | 08/24 | 04/25 | | |
NCT06377228: A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) |
|
|
| Not yet recruiting | 1 | 20 | NA | TAK-007, Chemotherapy Agents | Takeda | Refractory Lupus Nephritis | 04/29 | 04/29 | | |
| Recruiting | 1 | 24 | RoW | TAK-279, Placebo | Takeda | Healthy Volunteers | 12/24 | 12/24 | | |
NCT05992155: A Study of TAK-279 in Adults With or Without Kidney Problems |
|
|
| Completed | 1 | 24 | US | TAK-279 | Takeda | Renal Impairment, Healthy Volunteers | 05/24 | 05/24 | | |
NCT05891158: A Study About Fazirsiran in People With and Without Liver Problems |
|
|
| Recruiting | 1 | 41 | Europe | Fazirsiran, TAK-999 | Takeda | Hepatic Impairment | 04/25 | 04/25 | | |
| Active, not recruiting | 1 | 120 | Europe, US, RoW | Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide | Takeda | Multiple Myeloma | 01/24 | 06/24 | | |
NCT05702424: Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer |
|
|
| Active, not recruiting | 1 | 50 | US | IGM-7354 | IGM Biosciences, Inc. | Solid Tumor | 02/26 | 03/26 | | |
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy |
|
|
| Active, not recruiting | 1 | 16 | Europe, Japan, US, RoW | Mezagitamab, TAK-079 | Takeda | Kidney Disease, Glomerulonephritis | 03/26 | 03/26 | | |
NCT04506619 / 2020-002726-84: Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants |
|
|
| Terminated | N/A | 26 | Europe, US | No Intervention | Oak Hill Bio Ltd | Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity | 08/22 | 08/22 | | |
| Completed | N/A | 179 | Europe, Canada, RoW | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 02/23 | 02/23 | | |
INTUITION-CPF, NCT04844593: A Study Using Artificial Intelligence to Identify Adults With Complex Perianal Fistulas Associated With Crohn's Disease |
|
|
| Completed | N/A | 32 | Europe | | Takeda | Crohn Disease, Rectal Fistula | 02/23 | 04/24 | | |
NCT05795361: Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome |
|
|
| Available | N/A | | Europe, US, RoW | Idursulfase-IT, HGT-2310, TAK-609 | Takeda | Hunter Syndrome | | | | |
NCT05265078: A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi |
|
|
| Completed | N/A | 102 | Europe | | Takeda | Von Willebrand Disease (VWD) | 04/23 | 04/23 | | |
DOrianT, NCT04659798: A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice |
|
|
| Completed | N/A | 240 | Europe | | Takeda | Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis | 04/23 | 08/23 | | |
NCT04877431: A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease |
|
|
| Completed | N/A | 45 | RoW | | Takeda | Short Bowel Syndrome | 06/23 | 06/23 | | |
NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults |
|
|
| No Longer Available | N/A | | Europe, Canada, US | Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg | Shire, Takeda Development Center Americas, Inc. | Hereditary Angioedema (HAE), Angioedema | | | | |
| Completed | N/A | 48 | RoW | | Takeda | Angioedemas, Hereditary | 08/23 | 08/23 | | |
ermEX-20, NCT05419700: A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion |
|
|
| Completed | N/A | 76 | Europe | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 09/23 | 09/23 | | |
NCT05695560: A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers |
|
|
| Completed | N/A | 12 | Canada | No Intervention | Takeda | Von Willebrand Disease (VWD) | 11/23 | 11/23 | | |
| Active, not recruiting | N/A | 2800 | RoW | | Takeda | Lymphoma | 12/24 | 12/24 | | |
NCT05489640: A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home |
|
|
| Recruiting | N/A | 100 | Europe | No Intervention | Takeda | Hereditary Angioedema (HAE) | 06/24 | 06/24 | | |
PROSPECT, NCT05578417: A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada |
|
|
| Recruiting | N/A | 150 | Canada | No Intervention | Takeda | Hereditary Angioedema (HAE), Angioedema | 03/24 | 06/24 | | |
NCT03824522: Post Marketing Surveillance Study for ADYNOVATE in South Korea |
|
|
| Completed | N/A | 341 | RoW | ADYNOVATE, PEGylated rFVIII | Takeda, Takeda Pharma Korea Co. Ltd. | Hemophilia A | 01/24 | 01/24 | | |
NCT04885920: A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA) |
|
|
| Completed | N/A | 120 | Europe, RoW | | Takeda | Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative | 03/24 | 03/24 | | |
| Recruiting | N/A | 1000 | RoW | | Takeda | Lymphoma | 06/24 | 06/24 | | |
NCT05371028: A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada |
|
|
| Recruiting | N/A | 100 | Canada | Non-interventional Study | Takeda | Short Bowel Syndrome (SBS) | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 50 | Europe | No intervention | Takeda | Fabry Disease | 04/24 | 04/24 | | |
| Recruiting | N/A | 3000 | RoW | No Intervention | Jeil Pharmaceutical Co., Ltd. | Constipation | 05/24 | 11/24 | | |
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice |
|
|
| Active, not recruiting | N/A | 500 | RoW | | Takeda | Colitis, Ulcerative, Crohn Disease | 07/24 | 07/24 | | |
DRALEGA, NCT05982717: A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain |
|
|
| Recruiting | N/A | 250 | Europe | No intervention | Takeda | Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | 05/24 | 05/24 | | |
NCT04840680: A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM) |
|
|
| Recruiting | N/A | 165 | RoW | No Intervention | Takeda | Multiple Myeloma | 06/24 | 06/24 | | |
NCT05886478: A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin |
|
|
| Recruiting | N/A | 50 | Europe | No intervention | Takeda | T-Cell Lymphoma | 06/24 | 06/24 | | |
| Withdrawn | N/A | 30 | Europe | No Intervention | Takeda | Metachromatic Leukodystrophy (MLD) | 07/24 | 07/24 | | |
NCT06346899: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China |
|
|
| Not yet recruiting | N/A | 130 | RoW | No intervention | Takeda | Hereditary Angioedema (HAE) | 08/25 | 08/25 | | |
ENABLE, NCT04130191: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II |
|
|
| Active, not recruiting | N/A | 140 | Europe, RoW | | Shire, Takeda Development Center Americas, Inc. | Hereditary Angioedema (HAE) | 09/24 | 09/24 | | |
LANDSCAPE, NCT04943796: A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life |
|
|
| Recruiting | N/A | 576 | Europe, Canada | | Takeda | Attention Deficit Hyperactivity Disorder (ADHD) | 09/24 | 09/24 | | |
| Recruiting | N/A | 3000 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
NCT06104878: A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone |
|
|
| Withdrawn | N/A | 200 | RoW | No Intervention | Takeda | Hodgkin Lymphoma | 10/24 | 10/24 | | |
ELEGANT, NCT05737849: A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China |
|
|
| Withdrawn | N/A | 10800 | RoW | No Intervention | Takeda | Non-small Cell Lung Cancer (NSCLC) | 12/24 | 12/24 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 01/25 | 01/25 | | |
| Active, not recruiting | N/A | 72 | Europe, Canada, RoW | No Intervention | Takeda | Crohn's Disease | 01/25 | 01/25 | | |
PEDS, NCT04721366: A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease |
|
|
| Completed | N/A | 11 | US | Standard of Care, SOC | Takeda | Gaucher Disease | 04/23 | 04/23 | | |
NCT05626088: A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil |
|
|
| Recruiting | N/A | 2160 | RoW | No Intervention | Takeda | Ulcerative Colitis, Crohn's Disease | 01/25 | 01/25 | | |
HyMMy, NCT05879757: Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency |
|
|
| Recruiting | N/A | 100 | Europe, RoW | No Intervention | Takeda | Multiple Myeloma, Secondary Immunodeficiency (SID) | 07/25 | 03/26 | | |
| Recruiting | N/A | 111 | RoW | | Takeda | Multiple Myeloma | 08/25 | 08/25 | | |
VARIETY, NCT05384080: A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland |
|
|
| Active, not recruiting | N/A | 165 | Europe | | Takeda | Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis | 08/25 | 08/25 | | |
NCT05013190: A Study of NINLARO® in Chinese Adults With Multiple Myeloma |
|
|
| Recruiting | N/A | 320 | RoW | No intervention | Takeda | Multiple Myeloma | 10/25 | 10/25 | | |
NCT04961840: A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy |
|
|
| Active, not recruiting | N/A | 100 | US | No Intervention | Takeda | Constipation, Pregnancy | 12/25 | 12/25 | | |
NCT04799496: A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis |
|
|
| Recruiting | N/A | 600 | RoW | | Takeda | Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease | 01/26 | 01/26 | | |
| Recruiting | N/A | 40 | Europe | | Takeda | Hereditary Angioedema (HAE) | 03/26 | 03/26 | | |
NCT04869280: Post-Marketing Study of Prucalopride Safety In Pregnancy |
|
|
| Recruiting | N/A | 616 | US | No Intervention | Takeda, The Organization of Teratology Information Specialists | Chronic Idiopathic Constipation (CIC) | 05/26 | 05/26 | | |
| Recruiting | N/A | 70 | Europe | No Intervention | Takeda | Hodgkin Lymphoma | 06/26 | 06/26 | | |
NCT04838522: A Study of Prucalopride in Breastfeeding Women With Constipation |
|
|
| Recruiting | N/A | 12 | US | No Intervention | Takeda, UC San Diego Human Milk Research Biorepository | Chronic Idiopathic Constipation (CIC) | 12/26 | 12/26 | | |
NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS) |
|
|
| Recruiting | N/A | 3000 | Europe, RoW | | Shire, Takeda Development Center Americas, Inc. | Hereditary Angioedema (HAE) | 01/27 | 01/27 | | |
ENTIRETY, NCT05735327: A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | N/A | 50 | Europe | No intervention | Takeda | Non-small Cell Lung Cancer (NSCLC) | 06/27 | 06/27 | | |
NCT05428345: A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea |
|
|
| Recruiting | N/A | 600 | RoW | | Takeda | Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease (IBD) | 11/27 | 11/27 | | |
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A |
|
|
| Active, not recruiting | N/A | 207 | Europe, US, RoW | ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855 | Baxalta now part of Shire | Hemophilia A | 02/30 | 02/30 | | |
| Active, not recruiting | N/A | 1340 | Europe, Canada, US | No intervention | Takeda, Takeda Development Center Americas, Inc. | Hypoparathyroidism | 11/34 | 11/34 | | |
| Terkamp, Christoph |
| Active, not recruiting | N/A | 1340 | Europe, Canada, US | No intervention | Takeda, Takeda Development Center Americas, Inc. | Hypoparathyroidism | 11/34 | 11/34 | | |
| Vondran, Florian |
TaC:Drop, NCT06268769: Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs |
|
|
| Recruiting | 4 | 300 | Europe | Tacrolimus Pill, Envarsus, Tacrolimus capsule, Advagraf | Edward Geissler, Chiesi Pharmaceuticals GmbH | Immunosuppression | 12/26 | 09/29 | | |
| Plasmans, Anke |
SASC, NCT05641155: A Feasibility Study Evaluating the Performance of Focused Multipolar Stimulation and Sound Coding in Adults. |
|
|
| Recruiting | N/A | 20 | Europe, US | Focused Multipolar Stimulation (FMS) strategy | Cochlear | Hearing Impairment, Sensorineural | 10/24 | 05/25 | | |
CALOS4, NCT05709223: Comparing the Performance of a Categorical Loudness Scaling Based Fitting With a Behavioural Fitting in Adults With a Nucleus Cochlear Implant 3 Months Post-activation |
|
|
| Recruiting | N/A | 34 | Europe, US, RoW | Categorical loudness scaling based fitting using the Nexus Research System., The Nexus Research System., Behavioural fitting using Custom Sound Suite (CSS 6.3) Software | Cochlear, QbD Clinical, Avania | Hearing Loss | 03/25 | 03/25 | | |
| Buechner, ssor Andreas |
CALOS4, NCT05709223: Comparing the Performance of a Categorical Loudness Scaling Based Fitting With a Behavioural Fitting in Adults With a Nucleus Cochlear Implant 3 Months Post-activation |
|
|
| Recruiting | N/A | 34 | Europe, US, RoW | Categorical loudness scaling based fitting using the Nexus Research System., The Nexus Research System., Behavioural fitting using Custom Sound Suite (CSS 6.3) Software | Cochlear, QbD Clinical, Avania | Hearing Loss | 03/25 | 03/25 | | |
| Karst, Matthias |
ELEVATE, NCT05610813: Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain |
|
|
| Active, not recruiting | 3 | 384 | Europe | VER-01, trans-Δ9-Tetra-hydrocannabinol (THC), Opioid therapy, Opioids | Vertanical GmbH | Chronic Non-specific Low Back Pain | 12/24 | 12/24 | | |
